Immunotherapy-Induced Vogt Koyanagi Harada Syndrome: A Case Report

This report describes a case of Vogt Koyanagi Harada Disease (VKH) in a 44-year-old male with metastatic gastric carcinoma who presented with sudden onset headache and decreased vision. The patient was treated with first-line standard therapy for stage IV HER2-positive gastric adenocarcinoma and was on maintenance trastuzumab and pembrolizumab for seven months before developing new symptoms. His VKH was diagnosed after multiple imaging and a comprehensive ophthalmologic examination. The patient's vision and headaches improved with the initiation of corticosteroid therapy. Although immunotherapy was discontinued, trastuzumab was continued with close ophthalmology follow-up. He remains in stable condition despite his cancer. It is critical to consider and recognize immunotherapy-related ophthalmologic complications immediately, even if they are rare, considering their implications. Corticosteroids remain the first-line organ-saving therapy.